Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,865,218
  • Shares Outstanding, K 68,464
  • Annual Sales, $ 43,950 K
  • Annual Income, $ -154,940 K
  • EBIT $ -231 M
  • EBITDA $ -228 M
  • 60-Month Beta 1.07
  • Price/Sales 65.57
  • Price/Cash Flow N/A
  • Price/Book 4.10

Options Overview Details

View History
  • Implied Volatility 64.29% ( +7.75%)
  • Historical Volatility 49.25%
  • IV Percentile 55%
  • IV Rank 20.64%
  • IV High 147.11% on 05/16/24
  • IV Low 42.74% on 06/05/24
  • Put/Call Vol Ratio 22.94
  • Today's Volume 383
  • Volume Avg (30-Day) 470
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 12,228
  • Open Int (30-Day) 12,582

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.00
  • Number of Estimates 8
  • High Estimate -0.81
  • Low Estimate -1.37
  • Prior Year -1.09
  • Growth Rate Est. (year over year) +8.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.03 +2.00%
on 12/13/24
49.44 -15.35%
on 12/02/24
-1.08 (-2.52%)
since 11/20/24
3-Month
41.03 +2.00%
on 12/13/24
55.39 -24.44%
on 11/07/24
-7.82 (-15.74%)
since 09/20/24
52-Week
25.83 +62.02%
on 12/21/23
61.61 -32.07%
on 05/24/24
+15.97 (+61.71%)
since 12/20/23

Most Recent Stories

More News
Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab for Metastatic Colorectal Cancer

Merus N.V. has dosed the first patient in a phase 2 trial of petosemtamab for metastatic colorectal cancer.Quiver AI SummaryMerus N.V. has announced the dosing of the first patient in a phase 2 trial assessing...

MRUS : 41.85 (-0.57%)
Merus N.V. Updates on Petosemtamab Clinical Trials in Head and Neck Squamous Cell Carcinoma and Metastatic Colorectal Cancer

Merus announces ongoing trials of petosemtamab for head and neck and colorectal cancers, with data updates expected in 2025.Quiver AI SummaryMerus N.V. announced interim clinical results from its ongoing...

MRUS : 41.85 (-0.57%)
Merus N.V. Receives FDA Approval for BIZENGRI®: First Targeted Therapy for NRG1+ Advanced Pancreatic Adenocarcinoma and NSCLC

BIZENGRI® is the FDA-approved therapy for advanced pancreatic adenocarcinoma and NSCLC with NRG1 gene fusions, offering new treatment options.Quiver AI SummaryMerus N.V. has announced that the U.S. FDA...

MRUS : 41.85 (-0.57%)
Merus N.V. Announces Positive Phase 2 Interim Data for Petosemtamab Monotherapy in Second-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Petosemtamab shows promising results in treating recurrent/metastatic HNSCC; full data to be discussed on December 7.Quiver AI SummaryMerus N.V. announced the interim data from a Phase 2 trial of petosemtamab...

MRUS : 41.85 (-0.57%)
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns...

ONCY : 0.8310 (-6.36%)
HALO : 46.96 (-0.76%)
CADL : 8.75 (-12.15%)
MRUS : 41.85 (-0.57%)
RHHBY : 34.5000 (+0.76%)
ONC.TO : 1.19 (-9.16%)
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – Pancreatic cancer is among the...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
RHHBY : 34.5000 (+0.76%)
HALO : 46.96 (-0.76%)
CADL : 8.75 (-12.15%)
MRUS : 41.85 (-0.57%)
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates

/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...

ONCY : 0.8310 (-6.36%)
CADL : 8.75 (-12.15%)
AZN : 65.35 (+1.41%)
MRUS : 41.85 (-0.57%)
LTRN : 3.14 (-2.02%)
ONC.TO : 1.19 (-9.16%)
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024

USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
CADL : 8.75 (-12.15%)
AZN : 65.35 (+1.41%)
MRUS : 41.85 (-0.57%)
LTRN : 3.14 (-2.02%)
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
RHHBY : 34.5000 (+0.76%)
MRUS : 41.85 (-0.57%)
MGNX : 3.18 (unch)
IMRX : 2.00 (+8.70%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
PYXS : 1.6900 (+9.74%)
AZN : 65.35 (+1.41%)
LLY : 767.76 (+1.35%)
MRUS : 41.85 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is...

See More

Key Turning Points

3rd Resistance Point 44.54
2nd Resistance Point 43.90
1st Resistance Point 42.87
Last Price 41.85
1st Support Level 41.21
2nd Support Level 40.57
3rd Support Level 39.54

See More

52-Week High 61.61
Fibonacci 61.8% 47.94
Fibonacci 50% 43.72
Last Price 41.85
Fibonacci 38.2% 39.50
52-Week Low 25.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar